An interventional study of Safety Aid Reduction Treatment for PTSD in Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.
Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 180th largest by enrollment of the 246 interventional ones that give a count, is one of 14 that started in 2023, is one of 185 with no phase, and was the 177th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22–70
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–75
VA Office of Research and Development · Sites in United States
Ages 18–75
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
263 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 30 · Phase 3 10 · Phase 4 14
First in 2000; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 87 across the 246 interventional studies, 110 across the 17 observational. Of the 194 that completed or were terminated, 167 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
22 of the studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06000475VA Office of Research and DevelopmentEnhancing Memory in Cognitive Processing Therapy for PTSD | 2026-12-31 |
| NCT05812131VA Office of Research and DevelopmentCOPEWeb Training for Providers | 2027-01-01 |
| NCT05149534VA Office of Research and DevelopmentrTMS-augmented Written Exposure Therapy for PTSD | 2027-01-29 |
| NCT05776056VA Office of Research and DevelopmentMethylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints | 2027-03-31 |
| NCT05267665VA Office of Research and DevelopmentFamily Involvement in Treatment for PTSD (FIT-PTSD): A Brief, Feasible Method for Enhancing Outcomes, Retention, and Engagement | 2027-03-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) among Veterans with posttraumatic stress disorder (PTSD). It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.
Rates of posttraumatic stress disorder (PTSD) among military personnel have surged in recent years. In response, the Department of Veterans Affairs (VA) has launched nationwide training initiatives to disseminate two PTSD treatments with strong empirical support: prolonged exposure (PE) therapy and cognitive processing therapy (CPT). Despite the well-documented effectiveness of PE and CPT, only a minority of Veterans with PTSD initiate these trauma-focused treatments. One approach to addressing PTSD in a non-trauma-focused fashion is to utilize empirically supported treatments focused on safety aid reduction. Safety aids are maladaptive cognitive and/or behavioral strategies designed to prevent, avoid, or alleviate anxiety. Initially introduced as a way to explain how pathological anxiety can persist despite repeated exposure to feared stimuli, safety aids have been found to play a critical role in the etiology and maintenance of various anxiety and related conditions including PTSD. Importantly, a separate line of research suggests that safety aids are amenable to change through cognitive behavioral interventions. Although promising, these trials did not include patients with PTSD. In this context, the purpose of this project is to examine the acceptability, feasibility, and utility of a safety aid reduction treatment (START) for PTSD. Participants will include veterans with a diagnosis of PTSD who decline to participate in evidence-based psychotherapies (EBPs) for PTSD, namely PE or CPT. It is hypothesized that START will be acceptable, feasible, and will lead to reductions in PTSD symptom severity immediately and over time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active arm- START-PTSD
Behavioral: Safety Aid Reduction Treatment for PTSD
START-PTSD includes many of the key elements found in empirically supported treatments for PTSD including: a) psychoeducation regarding the development and maintenance of PTSD; and b) exposure to internal sensations and external situations that are connected to one's fear/distress response via identification and elimination of safety aids. Known safety aids to be covered include: cognitive avoidance (e.g., using mental distractions to avoid trauma-related images); situational avoidance (e.g., avoiding crowded market places); checking behaviors (e.g., checking doors, windows, locks, and perimeters more often than necessary); reassurance seeking (e.g., excessively watching the news); other compulsive behaviors (e.g., checking the location of exits); use of companions (e.g., relying on someone to attend a social gathering); and use of alcohol and certain substances (e.g., consuming alcohol to reduce anxiety).
Change in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
The CAPS-5 is a 30-item clinician-administered interview designed to assess current (i.e., past month) and lifetime PTSD diagnostic status. In addition to assessing the 20 DSM-5 PTSD symptoms, the CAPS-5 contains questions regarding the onset and duration of symptoms, associated impairment in various life domains, and specifications for the dissociative subtype. The past month CAPS-5 will be administered at baseline and one-month follow-up to assess changes in PTSD diagnostic status. Totals scores range 0-80, where higher scores indicating higher symptom severity.
Time frame: One-month follow-up
Change in PTSD Symptoms as Measured by the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)
The PCL-5 is a 20-item self-report questionnaire designed to assess each of the 20 DSM-5 PTSD symptoms. Veterans will be asked to read a list of symptoms and indicate their level of distress as it relates to each within the past month using a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (Extremely). Total scores can range from 0 to 80 with higher scores reflecting increased symptom severity. The PCL-5 will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD symptom severity.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Changes in Safety Aid Usage as Measured by the Safety Behavior Assessment Form (SBAF)
The SBAF is a 41-item self-report questionnaire designed to assess safety behavior usage. Veterans will be asked to read a list of behaviors and rate how often they engage in each behavior using a 4-point Likert-type scale ranging from 0 (Never) to 3 (Always). Total scores can range from 0 to 123 with higher scores reflecting increased symptom severity. The SBAF will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in safety behavior usage.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Client Satisfaction Questionnaire-8 (CSQ-8)
The CSQ-8 is an 8-item self-report questionnaire designed to assess overall satisfaction with treatment services. Although response options differ from item-to-item, all questions are rated on a 4-point Likert-type scale ranging from 1 to 4 (total scores ranging 8 - 32) with higher scores indicating higher treatment satisfaction. The CSQ-8 will be administered immediately following the 10-week group to assess treatment acceptability.
Time frame: Post-intervention (10-weeks)
Changes in Anxiety as Measured by the Beck Anxiety Inventory (BAI)
The BAI is a 21-item self-report questionnaire designed to assess the experience of anxiety symptoms. Veterans will be asked to rate how often they experience each symptom using a 4-point Likert-type scale ranging from 0 (Not at all) to 3 (Severely). Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BAI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in anxiety symptoms.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Changes in Depression as Measured by the Beck Depression Inventory-II (BDI-II)
The BDI-II is a 21-item self-report questionnaire designed to assess symptoms associated with depression. Using a 4-point Likert-type scale ranging from 0 to 3, Veterans will be asked to select the statement from a group of statements that best represents how they have felt over the last two weeks. Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BDI-II will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in depression symptoms.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Changes in PTSD Cognitions as Measured by the Posttraumatic Cognitions Inventory (PTCI)
The PTCI is a 33-item self-report questionnaire designed to assess trauma-related thoughts and beliefs including negative cognitions regarding the self, others, and the world. Veterans will be asked to read a list of statements and indicate the degree to which they agree or disagree with each statement using a 7-point Likert-type scale ranging from 1(totally disagree) to 7 (totally agree). Total scores can range from 33 to 231 with higher scores reflecting increased symptom severity. The PTCI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD cognitions.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Changes in Functional Impairment as Measured by the Sheehan Disability Scale (SDS)
The SDS is a 3-item self-report questionnaire designed to assess functional impairment functional impairment in work/school, social, and family life. For each domain, Veterans will be asked to provide an impairment rating ranging from 0 (Not at all) to 10 (Extremely). Total scores can range from 0 to 30 with higher scores reflecting increased impairment. The SDS will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in functional impairment.
Time frame: Post-intervention (10-weeks) and one-month follow-up
Veterans receiving care at the New Orleans VA were recruited over a two-year period from outpatient mental health. Specifically, Veterans with a diagnosis of PTSD who declined or prematurely dropped of trauma-focused treatment for PTSD were given information about the study and assessed for eligibility.
| Milestone | Active Arm- START-PTSD |
|---|---|
| Started | 45 |
| Completed | 31 |
| Not completed | 14 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 6 |
The CAPS-5 is a 30-item clinician-administered interview designed to assess current (i.e., past month) and lifetime PTSD diagnostic status. In addition to assessing the 20 DSM-5 PTSD symptoms, the CAPS-5 contains questions regarding the onset and duration of symptoms, associated impairment in various life domains, and specifications for the dissociative subtype. The past month CAPS-5 will be administered at baseline and one-month follow-up to assess changes in PTSD diagnostic status. Totals scores range 0-80, where higher scores indicating higher symptom severity.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Change in PTSD Diagnostic Status as Measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) | 27.89 ± 11.25 |
The PCL-5 is a 20-item self-report questionnaire designed to assess each of the 20 DSM-5 PTSD symptoms. Veterans will be asked to read a list of symptoms and indicate their level of distress as it relates to each within the past month using a 5-point Likert-type scale ranging from 0 (Not at all) to 4 (Extremely). Total scores can range from 0 to 80 with higher scores reflecting increased symptom severity. The PCL-5 will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD symptom severity.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 50.03 ± 17.97 |
| One-month follow-up | 50.04 ± 16.16 |
The SBAF is a 41-item self-report questionnaire designed to assess safety behavior usage. Veterans will be asked to read a list of behaviors and rate how often they engage in each behavior using a 4-point Likert-type scale ranging from 0 (Never) to 3 (Always). Total scores can range from 0 to 123 with higher scores reflecting increased symptom severity. The SBAF will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in safety behavior usage.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 67.10 ± 22.83 |
| One-month follow-up | 63.85 ± 21.92 |
The CSQ-8 is an 8-item self-report questionnaire designed to assess overall satisfaction with treatment services. Although response options differ from item-to-item, all questions are rated on a 4-point Likert-type scale ranging from 1 to 4 (total scores ranging 8 - 32) with higher scores indicating higher treatment satisfaction. The CSQ-8 will be administered immediately following the 10-week group to assess treatment acceptability.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Client Satisfaction Questionnaire-8 (CSQ-8) | 27.55 ± 3.20 |
The BAI is a 21-item self-report questionnaire designed to assess the experience of anxiety symptoms. Veterans will be asked to rate how often they experience each symptom using a 4-point Likert-type scale ranging from 0 (Not at all) to 3 (Severely). Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BAI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in anxiety symptoms.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 24.29 ± 11.38 |
| One-month follow-up | 27.11 ± 13.60 |
The BDI-II is a 21-item self-report questionnaire designed to assess symptoms associated with depression. Using a 4-point Likert-type scale ranging from 0 to 3, Veterans will be asked to select the statement from a group of statements that best represents how they have felt over the last two weeks. Total scores can range from 0 to 63 with higher scores reflecting increased symptom severity. The BDI-II will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in depression symptoms.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 24.73 ± 13.81 |
| One-month follow-up | 30.37 ± 15.74 |
The PTCI is a 33-item self-report questionnaire designed to assess trauma-related thoughts and beliefs including negative cognitions regarding the self, others, and the world. Veterans will be asked to read a list of statements and indicate the degree to which they agree or disagree with each statement using a 7-point Likert-type scale ranging from 1(totally disagree) to 7 (totally agree). Total scores can range from 33 to 231 with higher scores reflecting increased symptom severity. The PTCI will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in PTSD cognitions.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 134.37 ± 42.14 |
| One-month follow-up | 144.07 ± 46.64 |
The SDS is a 3-item self-report questionnaire designed to assess functional impairment functional impairment in work/school, social, and family life. For each domain, Veterans will be asked to provide an impairment rating ranging from 0 (Not at all) to 10 (Extremely). Total scores can range from 0 to 30 with higher scores reflecting increased impairment. The SDS will be administered at baseline, immediately following the 10-week group, and at a one-month follow-up to assess changes in functional impairment.
| Score on a scale | Active Arm- START-PTSD |
|---|---|
| Post-intervention (10-weeks) | 20.06 ± 6.02 |
| One-month follow-up | 19.67 ± 7.03 |
Collected over From enrollment until the end of the one-month follow-up (4-months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Arm- START-PTSD | 0/45 (0%) | 4/45 (8.9%) | 0/45 (0%) |
| Event | Active Arm- START-PTSD |
|---|---|
| Suicidal ideationPsychiatric disorders | 3/45 |
| Suicide attemptPsychiatric disorders | 1/45 |
| Age, Continuous(Years) | Active Arm- START-PTSD |
|---|---|
| Mean | 50.20 ± 13.07 |
| Sex: Female, Male(Participants) | Active Arm- START-PTSD |
|---|---|
| Female | 14 |
| Male | 31 |
| Race (NIH/OMB)(Participants) | Active Arm- START-PTSD |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 26 |
| White | 15 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Active Arm- START-PTSD |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 43 |
| Unknown or Not Reported | 0 |
| Clinician Administered PTSD Scale for DSM-5 (CAPS-5)(Score on a scale) | Active Arm- START-PTSD |
|---|---|
| Mean | 37.93 ± 9.60 |
| PTSD Checklist for DSM-5 (PCL-5)(Score on a scale) | Active Arm- START-PTSD |
|---|---|
| Mean | 58.91 ± 13.25 |
| Safety Behavior Assessment Form (SBAF)(Score on a scale) | Active Arm- START-PTSD |
|---|---|
| Median | 74.37 ± 18.09 |
| Beck Anxiety Inventory (BAI)(Score on a scale) | Active Arm- START-PTSD |
|---|---|
| Mean | 32.36 ± 13.42 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — There are no plans to disclose data outside of the VA, however, if there is a need to disclose data outside of the VA (e.g., a member of the scientific community requests a copy), IRB approval will be sought, data will be de-identified prior to disclosing, and the disclosure will be recorded on a VA disclosure log as required by VA policy.
Ran from Aug 2023 to primary completion in Sep 2025, 25 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 25 months is below that.
Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.
Start moved once since we started tracking on Sep 25, 2026: Sep 2024 → Aug 2023, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stress Disorders, Post-Traumatic →
VA Office of Research and Development →